Studies of long-term use of antidepressants: How should the data from them be interpreted?

CNS Drugs

Volumn 26, Issue 2, 2012, Pages 97-109

  El Mallakh, Rif S ^a   Briscoe, Brian ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Antidepressants; Depression; Drug withdrawal; Serotonin uptake inhibitors; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOSULEPIN; FLUOXETINE; IMIPRAMINE; LITHIUM; MIANSERIN; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

BIPOLAR DEPRESSION; COGNITIVE THERAPY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; DYSTHYMIA; HUMAN; MAJOR DEPRESSION; MEDLINE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STATISTICS AS TOPIC; TIME FACTORS;

EID: 84856455028     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11599450-000000000-00000     Document Type: Review

References (64)

1. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157: 229-33 (Pubitemid 30080902)
2. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999; 156: 1000-6 (Pubitemid 29302790)
3. Angst J. Course ofunipolar depressive, bipolar manicdepressive and schizoaffective disorders: results of a prospective longitudinal study [in German]. Fortschr Neurol Psychiatr Grenzgeb 1980; 48: 3-30
4. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280 (19): 1665-72 (Pubitemid 28532989)
5. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple treatments meta-analysis. Lancet 2009; 373 (9665): 746-58
6. Posternak MA, Solomon DA, Leon AC, et al. The naturalistic course of unipolar major depression in the absence of somatic therapy. J Nerv Ment Dis 2006; 194 (5): 324-9 (Pubitemid 43841196)
7. Greden JF. Physical symptoms of depression: unmet needs. J Clin Psychiatry 2003; 64 Suppl. 7: 5-11 (Pubitemid 36613198)
8. Judd LL, Paulus MJ, Schettler PS, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000; 157: 1501-4
9. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48 (9): 851-5
10. Gilaberte I, Montejo AL, de La Gandara J, et al., for the Fluoxetine Long-Term Study Group. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001; 21: 417-24 (Pubitemid 32673031)
11. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision): American Psychiatric Association. Am J Psychiatry 2000; 157 (4 Suppl.): 1-45
12. Glue P, Donovan MR, Kolluri S, et al. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry 2010; 44 (8): 697-705
13. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653-61 (Pubitemid 36246547)
14. Brunoni AR, Fraguas R, Fregni F. Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability. Ther Clin Risk Manag 2009; 5: 897-910
15. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998; 5: 293-306 (Pubitemid 28182534)
16. Papakostas GA, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors suboptimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 2010; 11 (2 Pt 2): 300-7
17. Papakostas GA, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008; 22 (8): 843-8
18. Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010; 71 (3): 270-9
19. Thase ME, Prichett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007; 27 (6): 672-6 (Pubitemid 351339455)
20. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-17 (Pubitemid 44807782)
21. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients: findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009; 43 (3): 215-29
22. Gitlin MJ, Abulseoud O, Frye MA. Improving the design of maintenance studies for bipolar disorder. Curr Med Res Opin 2010; 26 (8): 1835-42
23. Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl 2001; 42: S4-8 (Pubitemid 32846115)
24. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007; 9 (6): 449-59 (Pubitemid 350284935)
25. Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39: 1065-9 (Pubitemid 12020989)
26. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41: 1096-104 (Pubitemid 14017423)
27. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes of maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093-9
28. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769-73
29. Glen AI, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychol Med 1984; 14: 37-50 (Pubitemid 14025887)
30. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000; 57: 285-90 (Pubitemid 30140438)
31. Reynolds III CF, Ellen F, Perel J, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281: 39-45 (Pubitemid 29025098)
32. Old Age Depression Interest Group. How long should the elderly take antidepressants? A double-blind placebocontrolled study of continuation/ prophylaxis therapy with dothiepin. Br J Psychiatry 1993; 162: 175-82
33. Kishimoto A, MizukawaR, Matsuzaki F, et al. Prophylactic effect of mianserin on recurrent depression. Acta Psychiatr Scand 1994; 89: 46-51 (Pubitemid 24028265)
34. Robinson DS, Lerfald S, Bennett B, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 1991; 27: 31-9
35. Gilaberte I, Montejo AL, de la Gandara J, et al. Flouxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001; 21: 417-24 (Pubitemid 32673031)
36. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217-22
37. Wilson KCM, Mottram PG, Ashworth L, et al. Older community residents with depression: long-term treatment with sertraline. Br J Psychiatry 2003; 182: 492-7
38. Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001; 178: 304-10 (Pubitemid 32280923)
39. Reynolds III CF, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006; 354: 1130-8
40. Kocsis JH, Thase ME, Trivedi MH, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. J Clin Psychiatry 2007; 68: 1014-23 (Pubitemid 47340320)
41. Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of depression with VENlafaxine for Two years (PREVENT) study: outcome from the 2-year and combined maintenance phases. J Clin Psychiatry 2007; 68: 1246-56 (Pubitemid 47395628)
42. Segal ZV, Bieling P, Young T, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry 2010; 67 (12): 1256-64
43. Briscoe B, El-Mallakh RS. The evidence base for the longterm use of antidepressants as prophylaxis against future depressive episodes. Presented at the Annual Meeting of the American Psychiatric Association; 2010 May 24-26; New Orleans, (LA)
44. Greenhouse JB, Stangl D, Kupfer DJ, et al. Methodologic issues in maintenance therapy clinical trials. Arch Gen Psychiatry 1991; 48: 313-8
45. Lépine J-P, Caillard V, Bisserbe J-C, et al., for the PREVERS Investigators. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004; 161: 836-42 (Pubitemid 38625336)
46. Littrell J. Relationship between time since reuptake-blocker antidepressant discontinuation and relapse. Exp Clin Psychopharmacol 1994; 2 (1): 82-94
47. Franks MA, Macritchie KA, Mahmood T, et al. Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study. J Psychopharmacol 2008; 22 (4): 452-6 (Pubitemid 351989981)
48. Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67 Suppl. 4: 27-30 (Pubitemid 43764535)
49. Delgado PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry 2006; 67 Suppl. 4: 22-6 (Pubitemid 43764534)
50. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44 (2): 77-87 (Pubitemid 28305526)
51. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008; 22 (3): 330-2 (Pubitemid 351847442)
52. Baldessarini RJ, Tondo L, Ghiani C, et al. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167 (8): 934-41
53. Valuck RJ, Orton HD, Libby AM. Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study. J Clin Psychiatry 2009; 70 (8): 1069-77
54. Galbally M, Lewis AJ, Lum J, et al. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 2009; 43 (9): 846-54
55. Hale TW, Kendall-Tackett K, Cong Z, et al. Discontinuation syndrome in newborns whose mothers took antidepressants while pregnant or breastfeeding. Breastfeed Med 2010; 5: 283-8
56. El-Mallakh RS, Roberts RJ, Swann A, et al. Tardive dysphoria: antidepressant-induced chronic depression. Irish J Psychol Med. In press
57. El-Mallakh RS, Gao Y, Roberts RJ. Tardive dysphoria: the role of long term antidepressant use in inducing chronic depression. Med Hypotheses 2011; 76 (6): 769-73
58. Meshul CK, Casey DE. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res 1989; 489: 338-46 (Pubitemid 19149257)
59. El-Mallakh RS, Peters C, Waltrip C. Antidepressant treatment and neural plasticity. J Child Adoles Psychopharmacol 2000; 10: 287-94 (Pubitemid 32103904)
60. Getz A, Xu F, Zaidi W, et al. The antidepressant fluoxetine but not citalopram suppresses synapse formation and synaptic transmission between Lymnaea neurons by perturbing presynaptic and postsynaptic machinery. Eur J Neurosci 2011; 34 (2): 221-34
61. Djordjevic A, Djordjevic J, Elaković I, et al. Fluoxetine affects hippocampal plasticity, apoptosis and depressive-like behavior of chronically isolated rats. Prog Neuropscyhopharmacol Biol Psychiatry 2012 Jan 10; 36 (1): 92-100
62. Homberg JR, Olivier JD, Blom T, et al. Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One 2011; 6 (1): e16646
63. Wang Y, Neumann M, Hansen K, et al. Fluoxetine increases hippocampal neurogenesis and induces epigenetic factors but does not improve functional recovery after traumatic brain injury. J Neurotrauma 2011; 28 (2): 259-68
64. Bessa JM, Ferreira D, Melo I, et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 2009; 14 (8): 764-73